Buy or sell PHARMAJET stock pre IPO via an EquityZen fund
PharmaJet's devices provide for fixed dose needle-free jet injection for all three tissue depths (IM, SC, & ID).
About PHARMAJET Stock
PharmaJet is a user-friendly, inexpensive device for fluid injection into the body without a needle. Able to compete with traditional needle-syringe delivery, which inherently poses costly needle-stick, re-use and pass-along disease risk, the technology creates a positive ROI back for every injection. Unique in the field of jet injection because of its ability to reach all target tissues (IM, SC--0.5 mL, and ID--0.1 mL) accurately and comfortably, supported by wide regulatory claims (global and country specific) PharmaJet's platforms are the only commercially available devices that effectively address the 3 B annual immunization market. In addition to standard depth and dose delivery of any fluid, PharmaJet also has the ability to hyper-stimulate an improved immune response. The intradermal platform reduces the dose of vaccine by 60-80%, delivering into a 1.5-3mm tissue space in less than 1/10th of a second and achieving the same or superior immune response to a full intramuscular dose. For nucleic acid vaccines, both device platforms provide rapid delivery that helps negate the need for electroporation, while providing a several fold improved immune response versus needle based delivery. This is helping to facilitate vaccines gaining regulatory approval for solutions to pandemic threats and cancer vaccines, with a simple push and click.
Vice-Chairman, Global Business Development Officer, Co-Founder
Chairman and Chief Executive Officer
Chief Operating Officer